Virologic Aspects of Mucosal Transmission

Author(s): Zachary Ende, Martin J. Deymier, Eric Hunter*.

Journal Name: Current Immunology Reviews

Volume 15 , Issue 1 , 2019

Become EABM
Become Reviewer

Abstract:

The transmission of HIV is generally inefficient. Despite the development of a diverse viral quasispecies in a chronically infected individual, a severe genetic bottleneck is observed during transmission, leading to only one or a few genetic variants establishing infection. This genetic bottleneck is the result of both stochastic events and selection pressures, such that viruses with specific traits are favored during transmission. This chapter discusses current models of HIV mucosal transmission, evidence for selection of specific viral traits during this process, and the biological characterization of transmitted founder viruses based on monkey models and human cohorts. The impact of transmitted viral phenotypes on disease progression is also described. Understanding in greater depth the key viral features required for transmission will be essential to the development of effective interventions for HIV prevention.

Keywords: HIV, transmission, transmitted/founder, virology, immunology, AIDS, SIV.

[1]
Zhu T, Korber BT, Nahmias AJ, et al. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature 1998; 391: 594-7.
[2]
Worobey M, Gemmel M, Teuwen DE, et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008; 455: 661-4.
[3]
UNAIDS GLOBAL AIDSUP DATE 2016 2016; 1-16
[4]
Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: A systematic review and meta-analysis. Lancet Infect Dis 2008; 8: 553-63.
[5]
Royce RA, Seña A, Cates W, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997; 336: 1072-8.
[6]
Boily M-C, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: Systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9: 118-29.
[7]
Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med 2012; 2: a006965.
[8]
Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464: 217-23.
[9]
Zhang Z, Schuler T, Zupancic M, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999; 286: 1353-7.
[10]
Shang L, Duan L, Perkey KE, et al. Epithelium-innate immune cell axis in mucosal responses to SIV. Mucosal Immunol 2016; 10: 508-19.
[11]
Miller CJ, Li Q, Abel K, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79: 9217-27.
[12]
Zhang Z-Q, Wietgrefe SW, Li Q, et al. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci USA 2004; 101: 5640-5.
[13]
Li Q, Estes JD, Schlievert PM, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458: 1034-8.
[14]
Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 2005; 79: 12164-72.
[15]
Barouch DH, Ghneim K, Bosche WJ, et al. Rapid inflammasome activation following mucosal SIV infection of rhesus monkeys. Cell 2016; 165: 656-67.
[16]
Stieh DJ, Maric D, Kelley ZL, et al. Vaginal challenge with an SIV-based dual reporter system reveals that infection can occur throughout the upper and lower female reproductive tract. PLoS Pathog 2014; 10: e1004440.
[17]
Stieh DJ, Matias E, Xu H, et al. Th17 cells are preferentially infected very early after vaginal transmission of SIV in macaques. Cell Host Microbe 2016; 19: 529-40.
[18]
Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4+ T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008; 112: 2826-35.
[19]
Cecchinato V, Trindade CJ, Laurence A, et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol 2008; 1: 279-88.
[20]
Prendergast A, Prado JG, Kang Y-H, et al. HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS 2010; 24: 491-502.
[21]
Pallikkuth S, Micci L, Ende ZS, et al. Maintenance of intestinal Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with (IL)-21. PLoS Pathog 2013; 9: e1003471.
[22]
McGary CS, Alvarez X, Harrington S, et al. The loss of CCR6(+) and CD161(+) CD4(+) T-cell homeostasis contributes to disease progression in SIV-infected rhesus macaques. Mucosal Immunol 2017; 10(4): 1082-96.
[23]
Macal M, Sankaran S, Chun TW, et al. Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol 2008; 1: 475-88.
[24]
Schuetz A, Deleage C, Sereti I, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog 2014; 10: e1004543.
[25]
Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921-9.
[26]
Fideli US, Allen SA, Musonda R, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001; 17: 901-10.
[27]
Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One 2010; 5: e12598.
[28]
Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3: 77ra29.
[29]
Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA 1996; 275: 599-605.
[30]
Dickover RE, Dillon M, Leung KM, et al. Early prognostic indicators in primary perinatal human immunodeficiency virus type 1 infection: importance of viral RNA and the timing of transmission on long-term outcome. J Infect Dis 1998; 178: 375-87.
[31]
Ludlam CA, Tucker J, Steel CM, et al. Human T-Lymphotropic Virus type III (HTLV-III) infection in seronegative haemophiliacs after transfusion of factor VIII. Lancet 1985; 2: 233-6.
[32]
Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21: 1723-30.
[33]
Liu J, Keele BF, Li H, et al. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol 2010; 84: 10406-12.
[34]
Keele BF, Li H, Learn GH, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206: 1117-34.
[35]
Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2: 33-42.
[36]
Passmore J-AS, Jaspan HB, Masson L. Genital inflammation, immune activation and risk of sexual HIV acquisition. Curr Opin HIV AIDS 2016; 11: 156-62.
[37]
Anahtar MN, Byrne EH, Doherty KE, et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 2015; 42: 965-76.
[38]
Gosmann C, Anahtar MN, Handley SA, et al. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women. Immunity 2017; 46: 29-37.
[39]
Baggaley RF, White RG, Boily M-C. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010; 39: 1048-63.
[40]
Masson L, Passmore J-AS, Liebenberg LJ, et al. Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis 2015; 61: 260-9.
[41]
Haaland RE, Hawkins PA, Salazar-Gonzalez J, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009; 5: e1000274.
[42]
Miller WC, Rosenberg NE, Rutstein SE, Powers KA. Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5: 277-82.
[43]
Brenner BG, Roger M, Routy J-P, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195: 951-9.
[44]
Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191: 1403-9.
[45]
Ananworanich J, Sacdalan CP, Pinyakorn S, et al. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. J Virus Erad 2016; 2: 43-8.
[46]
Robb ML, Eller LA, Kibuuka H, et al. Prospective study of acute HIV-1 infection in adults in East Africa and Thailand. N Engl J Med 2016; 374: 2120-30.
[47]
Murphy MK, Yue L, Pan R, et al. Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 2013; 9: e1003173.
[48]
Ma Z-M, Stone M, Piatak M, et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 2009; 83: 3288-97.
[49]
Wolinsky SM, Wike CM, Korber BT, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992; 255: 1134-7.
[50]
Wolfs TF, Zwart G, Bakker M, Goudsmit J. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission. Virology 1992; 189: 103-10.
[51]
Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261: 1179-81.
[52]
Zhang LQ, MacKenzie P, Cleland A, et al. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993; 67: 3345-56.
[53]
Kleim JP, Ackermann A, Brackmann HH, Gahr M, Schneweis KE. Epidemiologically closely related viruses from hemophilia B patients display high homology in two hypervariable regions of the HIV-1 env gene. AIDS Res Hum Retroviruses 1991; 7: 417-21.
[54]
Simmonds P, Zhang LQ, McOmish F, et al. Discontinuous sequence change of Human Immunodeficiency Virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: Implications for models of HIV pathogenesis. J Virol 1991; 65: 6266-76.
[55]
Pang S, Shlesinger Y, Daar ES, et al. Rapid generation of sequence variation during primary HIV-1 infection. AIDS 1992; 6: 453.
[56]
Nowak MA, Anderson RM, McLean AR, et al. Antigenic diversity thresholds and the development of AIDS. Science 1991; 254: 963-9.
[57]
McKenna SL, Muyinda GK, Roth D, et al. Rapid HIV testing and counseling for voluntary testing centers in Africa. AIDS 1997; 11(Suppl. 1): S103-10.
[58]
Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004; 303: 2019-22.
[59]
Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206(6): 1273-89.
[60]
Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Aca Sci 2008; 105: 7552-7.
[61]
Ochsenbauer C, Edmonds TG, Ding H, et al. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4+ T lymphocytes and monocytederived macrophages. J Virol 2012; 86: 2715-28.
[62]
Parrish NF, Gao F, Li H, et al. Phenotypic properties of transmitted founder HIV-1. Pro Nat Aca Sci 2013; 10: 6626-33.
[63]
Deymier MJ, Ende Z, Fenton-May AE, et al. Heterosexual transmission of subtype C HIV-1 selects consensus-like variants without increased replicative capacity or interferon-α resistance. PLoS Pathog 2015; 11: e1005154.
[64]
Salazar-Gonzalez JF, Bailes E, Pham KT, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82: 3952-70.
[65]
Lee HY, Giorgi EE, Keele BF, et al. Modeling sequence evolution in acute HIV-1 infection. J Theor Biol 2009; 261: 341-60.
[66]
Abrahams M-R, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 2009; 83: 3556-67.
[67]
Sagar M, Lavreys L, Baeten JM, et al. Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. AIDS 2004; 18: 615-9.
[68]
Li H, Bar KJ, Wang S, et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog 2010; 6: e1000890.
[69]
Masharsky AE, Dukhovlinova EN, Verevochkin SV, et al. A substantial transmission bottleneck among newly and recently HIV-1-infected injection drug users in St Petersburg, Russia. J Infect Dis 2010; 201: 1697-702.
[70]
Bar KJ, Li H, Chamberland A, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010; 84: 6241-7.
[71]
Tully DC, Ogilvie CB, Batorsky RE, et al. Differences in the selection bottleneck between modes of sexual transmission influence the genetic composition of the HIV-1 founder virus. PLoS Pathog 2016; 12: e1005619.
[72]
Samleerat T, Braibant M, Jourdain G, et al. Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01_AE. J Infect Dis 2008; 198: 868-76.
[73]
Verhofstede C, Demecheleer E, De Cabooter N, et al. Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A. J Virol 2003; 77: 3050-7.
[74]
Russell ES, Kwiek JJ, Keys J, et al. The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population. J Virol 2011; 85: 8253-62.
[75]
Nowak P, Karlsson AC, Naver L, et al. The selection and evolution of viral quasispecies in HIV-1 infected children. HIV Med 2002; 3: 1-11.
[76]
Pasquier C, Cayrou C, Blancher A, et al. Molecular evidence for mother-to-child transmission of multiple variants by analysis of RNA and DNA sequences of human immunodeficiency virus type 1. J Virol 1998; 72: 8493-501.
[77]
Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17: 1871-9.
[78]
Stone M, Keele BF, Ma Z-M, et al. A limited number of Simian Immunodeficiency Virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010; 84: 7083-95.
[79]
Ma Z-M, Keele BF, Qureshi H, et al. SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma. AIDS Res Hum Retroviruses 2011; 27: 1259-69.
[80]
Roos MT, Lange JM, de Goede RE, et al. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis 1992; 165: 427-32.
[81]
Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272: 1955-8.
[82]
Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-7.
[83]
Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
[84]
Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-73.
[85]
Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-48.
[86]
Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
[87]
Björndal A, Deng H, Jansson M, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71: 7478-87.
[88]
Berson JF, Long D, Doranz BJ, et al. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996; 70: 6288-95.
[89]
Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-77.
[90]
Michael NL, Chang G, Louie LG, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997; 3: 338-40.
[91]
Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-5.
[92]
Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: Studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997; 3: 23-36.
[93]
Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-62.
[94]
Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: The “gatekeeper” problem resolved? Nat Rev Microbiol 2006; 4: 312-7.
[95]
Liu A, Yang Y, Liu L, et al. Differential compartmentalization of HIV-targeting immune cells in inner and outer foreskin tissue. PLoS One 2014; 9: e85176.
[96]
Sagar M, Laeyendecker O, Lee S, et al. Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis 2009; 199: 580-9.
[97]
Alizon S, Fraser C. Within-host and between-host evolutionary rates across the HIV-1 genome. Retrovirology 2013; 10: 49-59.
[98]
Redd AD, Collinson-Streng AN, Chatziandreou N, et al. Previously transmitted HIV-1 strains are preferentially selected during subsequent sexual transmissions. J Infect Dis 2012; 206: 1433-42.
[99]
Carlson JM, Schaefer M, Monaco DC, et al. HIV transmission. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science 2014; 345: 1254031-3.
[100]
Ahmad N, Baroudy BM, Baker RC, Chappey C. Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission. J Virol 1995; 69: 1001-12.
[101]
Zhu T, Wang N, Carr A, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996; 70: 3098-107.
[102]
Boeras DI, Hraber PT, Hurlston M, et al. Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proc Natl Acad Sci USA 2011; 108: E1156-63.
[103]
Baalwa J, Wang S, Parrish NF, et al. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology 2013; 436: 33-48.
[104]
Long EM, Rainwater SMJ, Lavreys L, Mandaliya K, Overbaugh J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 2002; 18: 567-76.
[105]
Isaacman-Beck J, Hermann EA, Yi Y, et al. Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J Virol 2009; 83: 8208-20.
[106]
Chalmet K, Dauwe K, Foquet L, et al. Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: Correlates and evidence for transmission. J Infect Dis 2012; 205: 174-84.
[107]
Huang W, Eshleman SH, Toma J, et al. Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan mother-infant pairs. AIDS 2009; 23: 1903-8.
[108]
Sheppard HW, Celum C, Michael NL, et al. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr 2002; 29: 307-13.
[109]
Gnanakaran S, Bhattacharya T, Daniels M, et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog 2011; 7: e1002209.
[110]
Terahara K, Ishige M, Ikeno S, et al. Humanized mice dually challenged with R5 and X4 HIV-1 show preferential R5 viremia and restricted X4 infection of CCR5(+)CD4(+) T cells. Microbes Infect 2015; 17: 378-86.
[111]
Pandrea I, Parrish NF, Raehtz K, et al. Mucosal simian immunodeficiency virus transmission in African green monkeys: susceptibility to infection is proportional to target cell availability at mucosal sites. J Virol 2012; 86: 4158-68.
[112]
Pandrea I, Onanga R, Souquiere S, et al. Paucity of CD4+ CCR5+ T cells may prevent transmission of simian immunodeficiency virus in natural nonhuman primate hosts by breast-feeding. J Virol 2008; 82: 5501-9.
[113]
Hladik F, Sakchalathorn P, Ballweber L, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26: 257-70.
[114]
Alexander M, Lynch R, Mulenga J, et al. Donor and recipient Envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry. J Virol 2010; 84: 4100-4.
[115]
Chohan B, Lang D, Sagar M, et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005; 79: 6528-31.
[116]
Frost SDW, Liu Y, Pond SLK, et al. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol 2005; 79: 6523-7.
[117]
Wilen CB, Parrish NF, Pfaff JM, et al. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol 2011; 85: 8514-27.
[118]
Li B, Decker JM, Johnson RW, et al. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 2006; 80: 5211-8.
[119]
Rong R, Gnanakaran S, Decker JM, et al. Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol 2007; 81: 5658-68.
[120]
Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307-12.
[121]
Parrish NF, Wilen CB, Banks LB, et al. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog 2012; 8: e1002686.
[122]
Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB. Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood 2012; 120: 2836-42.
[123]
Oberle CS, Joos B, Rusert P, et al. Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. Retrovirology 2016; 13: 62-82.
[124]
Arthos J, Cicala C, Martinelli E, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008; 9: 301-9.
[125]
Cicala C, Martinelli E, McNally JP, et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci USA 2009; 106: 20877-82.
[126]
Hawkins RA, Rank RG, Kelly KA. Expression of mucosal homing receptor alpha4beta7 is associated with enhanced migration to the Chlamydia-infected murine genital mucosa in vivo. Infect Immun 2000; 68: 5587-94.
[127]
Nawaz F, Cicala C, Van Ryk D, et al. The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α(4) β(7)+/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog 2011; 7: e1001301.
[128]
Richardson SI, Gray ES, Mkhize NN, et al. South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication. Retrovirology 2015; 12: 54.
[129]
Byrareddy SN, Kallam B, Arthos J, et al. Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection. Nat Med 2014; 20: 1397-400.
[130]
Ansari AA, Reimann KA, Mayne AE, et al. Blocking of α4β7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol 2011; 186: 1044-59.
[131]
Byrareddy SN, Arthos J, Cicala C, et al. Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy. Science 2016; 354: 197-202.
[132]
Selhorst P, Masson L, Ismail SD, et al. Cervicovaginal inflammation facilitates acquisition of less infectious HIV variants. Clin Infect Dis 2016; 64: 79-82.
[133]
Deymier MJ, Claiborne DT, Ende Z, et al. Particle infectivity of HIV-1 full-length genome infectious molecular clones in a subtype C heterosexual transmission pair following high fidelity amplification and unbiased cloning. Virology 2014; 468-470C: 454-61.
[134]
Iyer SS, Bibollet-Ruche F, Sherrill-Mix S, et al. Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. Proc Natl Acad Sci USA 2017; 114: e590-9.
[135]
Asmal M, Hellmann I, Liu W, et al. A signature in HIV-1 envelope leader peptide associated with transition from acute to chronic infection impacts envelope processing and infectivity. PLoS One 2011; 6: e23673.
[136]
Brockman MA, Brumme ZL, Brumme CJ, et al. Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol 2010; 84: 11937-49.
[137]
Wright JK, Brumme ZL, Carlson JM, et al. Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J Virol 2010; 84: 10820-31.
[138]
Prince JL, Claiborne DT, Carlson JM, et al. Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog 2012; 8: e1003041.
[139]
Claiborne DT, Prince JL, Scully E, et al. Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. Proc Natl Acad Sci USA 2015; 112: E1480-9.
[140]
Sakai K, Chikata T, Brumme ZL, et al. Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals. Retrovirology 2015; 12: 98.
[141]
Yue L, Pfafferott KJ, Baalwa J, et al. Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. PLoS Pathog 2015; 11: e1004565.
[142]
Wright JK, Novitsky V, Brockman MA, et al. Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. J Virol 2011; 85: 3996-4006.
[143]
Etemad B, Gonzalez OA, White L, et al. Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users. Retrovirology 2014; 11: 106-21.
[144]
Pena-Cruz V, Etemad B, Chatziandreou N, et al. HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners. Retrovirology 2013; 10: 162-78.
[145]
Utay NS, Douek DC. Interferons and HIV Infection: The good, the bad, and the ugly. Pathog Immun 2016; 1: 107-16.
[146]
Pitha PM. Innate antiviral response: Role in HIV-1 infection. Viruses 2011; 3: 1179-203.
[147]
Schneider WM, Chevillotte MD, Rice CM. Interferon-Stimulated Genes: A Complex Web of Host Defenses. Annu Rev Immunol 2014; 32: 513-45.
[148]
Katze MG, He Y, Gale M. Viruses and interferon: A fight for supremacy. Nat Rev Immunol 2002; 2: 675-87.
[149]
Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 2010; 8: 55-67.
[150]
Chang JJ, Altfeld M. Innate immune activation in primary HIV-1 infection. J Infect Dis 2010; 202(Suppl. 2): S297-301.
[151]
Veazey RS, Pilch-Cooper HA, Hope TJ, et al. Prevention of SHIV transmission by topical IFN-β treatment. Mucosal Immunol 2016; 9: 1528-36.
[152]
Sandler NG, Bosinger SE, Estes JD, et al. Type I interferon responses in rhesus macaquesprevent SIV infection and slow disease progression. Nature 2015; 511: 601-5.
[153]
Fenton-May AE, Dibben O, Emmerich T, et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 2013; 10: 146-64.
[154]
Foster TL, Wilson H, Iyer SS, et al. Resistance of Transmitted Founder HIV-1 to IFITM-mediated restriction. Cell Host Microbe 2016; 20: 429-42.
[155]
Kmiec D, Iyer SS, Stürzel CM, et al. Vpu-mediated counteraction of tetherin is a major determinant of HIV-1 interferon resistance. MBio 2016; 7: E00934-16.
[156]
Boyd DF, Sharma A, Humes D, Cheng-Mayer C, Overbaugh J. Adapting SHIVs in vivo selects for envelope-mediated interferon-α resistance. PLoS Pathog 2016; 12: e1005727.
[157]
Ribeiro CMS, Sarrami-Forooshani R, Setiawan LC, et al. Receptor usage dictates HIV-1 restriction by human TRIM5α in dendritic cell subsets. Nature 2016; 540: 448-52.
[158]
Song H, Hora B, Giorgi EE, et al. Transmission of multiple HIV-1 subtype C transmitted/founder viruses into the same recipients was not determined by modest phenotypic differences. Sci Rep 2016; 6: 38130.
[159]
Mlcochova P, Apolonia L, Kluge SF, et al. Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection. Virology 2015; 482: 72-8.
[160]
Shirazi Y, Pitha PM. Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle. J Virol 1992; 66: 1321-8.
[161]
Vendrame D, Sourisseau M, Perrin V, Schwartz O, Mammano F. Partial inhibition of human immunodeficiency virus replication by type I interferons: Impact of cell-to-cell viral transfer. J Virol 2009; 83: 10527-37.
[162]
Harper MS, Guo K, Gibbert K, et al. Interferon-α subtypes in an ex vivo model of acute HIV-1 infection: Expression, potency and effector mechanisms. PLoS Pathog 2015; 11: e1005254.
[163]
Lavender KJ, Gibbert K, Peterson KE, et al. Interferon alpha subtype-specific suppression of HIV-1 infection in vivo. J Virol 2016; 90: 6001-13.
[164]
Fraser C, Lythgoe K, Leventhal GE, et al. Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective. Science 2014; 343: 1243727.
[165]
Yue L, Prentice HA, Farmer P, et al. Cumulative impact of host and viral factors on HIV-1 viral-load control during early infection. J Virol 2013; 87: 708-15.
[166]
Carlson JM, Du VY, Pfeifer N, et al. Impact of pre-adapted HIV transmission. Nat Med 2016; 22: 606-13.
[167]
Lingappa JR, Thomas KK, Hughes JP, et al. Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters. AIDS Res Hum Retroviruses 2013; 29: 164-71.
[168]
Hecht FM, Hartogensis W, Bragg L, et al. HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS 2010; 24: 941-5.
[169]
Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-9.
[170]
Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-54.
[171]
Goepfert PA, Lumm W, Farmer P, et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med 2008; 205: 1009-17.
[172]
Chopera DR, Woodman Z, Mlisana K, et al. Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS Pathog 2008; 4: e1000033.
[173]
Monaco DC, Dilernia DA, Fiore-Gartland A, et al. Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV-1 disease progression. J Exp Med 2016; 213(10): 2049-63.
[174]
Sagar M, Lavreys L, Baeten JM, et al. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol 2003; 77: 12921-6.
[175]
Janes H, Herbeck JT, Tovanabutra S, et al. HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nat Med 2015; 21: 1139-47.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2019
Page: [14 - 27]
Pages: 14
DOI: 10.2174/1573395514666180626151737

Article Metrics

PDF: 40
HTML: 6